Other News To Note
Wednesday, March 6, 2013
Dako, of Glostrup, Denmark, part of Agilent Technologies Co., received FDA approval for the addition of Kadcyla (ado-trastuzumab emtansine) to the labeling of two Dako companion diagnostic assays. Kadcyla is marketed by Roche AG unit Genentech Inc., of South San Francisco.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.